• Frenos

  Participated · Seed · Jul 2026

  Frenos provides an OT security platform that builds a digital twin of a customer's network and uses its AI reasoning agent, SAIRA, to run fully simulated penetration tests that mimic attacker behavior without scanning hardware or risking production. The platform prioritizes exploitable attack paths and reduces assessment time from months to minutes with zero operational impact. Frenos reported strong growth metrics: ARR up more than 10x since early 2025, 215% revenue growth in H1 2026, a 2.7x year-over-year increase in pipeline, a fivefold rise in average deal size, and 2026 bookings already quadrupling full-year 2025. In one customer environment, SAIRA analyzed over 12,000 OT vulnerability findings and surfaced the eight that were actually exploitable, cutting remediation noise by 99.9%. The company is launching SAIRA Co-Work to provide a persistent OT security co-worker and is researching a next-generation foundation model for long-context reasoning and autonomous workflows. Frenos is based in Fulton, Md.

• Icarus Medical

  Participated · Series A · Jun 2026

  Icarus Medical develops a new class of orthopedic bracing technologies that combine biomechanics, software, and additive manufacturing to address osteoarthritis, post-operative recovery, neurological conditions, and complex lower-extremity mobility challenges. Key products include the Ascender Knee Brace for patellofemoral and multicompartment osteoarthritis and the Adonis Joint Distraction Knee Brace for unicompartmental osteoarthritis. The company designs and manufactures its products in Charlottesville, Virginia, and plans to expand manufacturing capacity as part of its growth strategy. Icarus intends to advance clinical validation of its devices while accelerating commercialization across the U.S. and hiring additional personnel. Its recent recognition includes placement on the Inc. 5000 list for 1,283% three-year growth and the 2026 CBIC Startup of the Year Award.

• Scamnetic

  Participated · Series A · Apr 2025

  Scamnetic develops patented AI scam-detection technology that can be integrated into enterprise platforms to help service providers safeguard consumers. Its product suite includes Scan&Score for scanning messages, websites, QR codes and images; IDeveryone for identity verification across video, audio and text; a 24/7 Scam Intervention hotline; and Scam Education resources. The company said the new funds will be used to expand marketing, sales and customer support and to accelerate its product roadmap. Scamnetic plans enhanced core features, stronger global coverage and deeper customer lifecycle support in response to rising global demand. The announcement highlights the high market need for scam protection given growing losses to fraud and scams cited in the release. The company is based in Tampa, Fla.

• Poppy Flowers

  Participated · Series A · Dec 2023

  Founded in 2019, Charlottesville-based Poppy Flowers operates a technology-driven marketplace that matches couples with local floral designers whose style, budget, and vision align with their needs. The company has already served more than 6,000 couples nationwide, positioning itself as a fast-growing player in the $71 billion U.S. floral industry. Poppy’s platform streamlines the traditionally fragmented wedding-florist experience by handling design matching, logistics, and fulfillment. With fresh capital, the team plans to accelerate an expansion into business-to-business offerings, roll out new technology features, and hire key leadership roles. Management believes these moves will widen its customer base beyond consumer weddings and deepen engagement with professional florists. Investors cite the company’s clear category leadership and scalable model as reasons for continued support. Financial details beyond the most recent and prior capital raises were not disclosed in the article.

• Previse

  Participated · Seed · Mar 2023

  Previse, recently rebranded from Capsulomics, is a precision-oncology company focused on the early detection and prevention of cancer, beginning with esophageal malignancies. Its first laboratory-developed test, Esopredict™, analyzes DNA methylation changes in four genes from Barrett’s esophagus tissue to generate an Esoscore™ that forecasts a patient’s five-year risk of developing high-grade dysplasia or esophageal cancer. The test equips gastroenterologists with data to personalize surveillance and treatment, aiming to improve outcomes in a cancer that currently has only a 20 % five-year survival rate. Previse’s technology stems from decades of research in the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine and was advanced with National Institutes of Health grants. Following the launch of Esopredict™, the company intends to expand commercial operations and undertake prospective clinical-utility studies to secure broad insurance coverage and reimbursement. Financially, Previse has just raised a $3 million seed round to support these initiatives.

No current team members are available.